Innovative Hypertension Treatment Recor Medical has pioneered the Paradise Ultrasound Renal Denervation system, FDA approved and recently launched in the US, positioning it as a cutting-edge solution for hypertension management with a strong growth potential in the medical device market.

Strategic Industry Positioning As a subsidiary of Otsuka Medical Devices, Recor benefits from robust backing and industry credibility, enabling partnerships and facilitating sales in the competitive hypertension treatment sector against established giants like Medtronic and Boston Scientific.

Recent Product Launches The recent launch of the Paradise uRDN system and upcoming FDA approval votes indicate expanding product offerings, creating opportunities to engage healthcare providers and clinics interested in innovative, minimally invasive hypertension therapies.

Growth and Funding With revenue estimates between 50 and 100 million dollars and a recent funding round of 10 million dollars, Recor demonstrates financial stability and a growth trajectory ideal for scaling sales efforts and entering new markets.

Market Expansion Potential Recor’s international presence, regulatory milestones, and focus on innovative renal denervation technologies suggest ample opportunities to target hospitals, cardiology clinics, and healthcare providers seeking advanced solutions for hypertension treatment.